113 related articles for article (PubMed ID: 36872555)
21. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
22. Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study.
Ravikumar R; Sabin C; Abu Hilal M; Bramhall S; White S; Wigmore S; Imber CJ; Fusai G;
J Am Coll Surg; 2014 Mar; 218(3):401-11. PubMed ID: 24484730
[TBL] [Abstract][Full Text] [Related]
23. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy.
Hue JJ; Sugumar K; Markt SC; Hardacre JM; Ammori JB; Rothermel LD; Winter JM; Ocuin LM
Surgery; 2021 Jul; 170(1):207-214. PubMed ID: 33454134
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
[TBL] [Abstract][Full Text] [Related]
25. McGill Brisbane Symptom Score for patients with resectable pancreatic head adenocarcinoma.
Jamal MH; Doi SA; Moser AJ; Dumitra S; abou Khalil J; Simoneau E; Chaudhury P; Onitilo AA; Metrakos P; Barkun JS
World J Gastroenterol; 2014 Sep; 20(34):12226-32. PubMed ID: 25232256
[TBL] [Abstract][Full Text] [Related]
26. A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas.
Marmor S; Burke EE; Virnig BA; Jensen EH; Tuttle TM
Cancer; 2016 Nov; 122(21):3378-3385. PubMed ID: 27419382
[TBL] [Abstract][Full Text] [Related]
27. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
[TBL] [Abstract][Full Text] [Related]
28. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.
Javed AA; Wright MJ; Siddique A; Blair AB; Ding D; Burkhart RA; Makary M; Cameron JL; Narang A; Herman J; Zheng L; Laheru D; Weiss MJ; Wolfgang C; He J
J Gastrointest Surg; 2019 Jan; 23(1):112-121. PubMed ID: 30242644
[TBL] [Abstract][Full Text] [Related]
29. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
[TBL] [Abstract][Full Text] [Related]
30. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer.
Merkow RP; Bilimoria KY; Tomlinson JS; Paruch JL; Fleming JB; Talamonti MS; Ko CY; Bentrem DJ
Ann Surg; 2014 Aug; 260(2):372-7. PubMed ID: 24374509
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis.
Uson Junior PLS; Carvalho L; Fernandes MLC; Botrus G; de Souza Martins R; da Silva EF; Dos Santos SSMB; Taniwaki L; Taranto P; Dutra ACP; de Oliveira Filho JB; Araujo SEA; Moura F
Sci Rep; 2022 Aug; 12(1):13592. PubMed ID: 35948602
[TBL] [Abstract][Full Text] [Related]
32. Clinical predictors of resectability of pancreatic adenocarcinoma.
Almadi MA; Alharbi O; Azzam N; Altayeb M; Javed M; Alsaif F; Hassanain M; Alsharabi A; Al-Saleh K; Aljebreen AM
Saudi J Gastroenterol; 2013; 19(6):278-85. PubMed ID: 24195982
[TBL] [Abstract][Full Text] [Related]
33. Sociodemographic Disparities in the Receipt of Adjuvant Chemotherapy Among Patients With Resected Stage I-III Pancreatic Adenocarcinoma.
Sanford NN; Aguilera TA; Folkert MR; Ahn C; Mahal BA; Zeh H; Beg MS; Mansour J; Sher DJ
J Natl Compr Canc Netw; 2019 Nov; 17(11):1292-1300. PubMed ID: 31693987
[TBL] [Abstract][Full Text] [Related]
34. Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing.
Lee AJ; Simoneau E; Chiang YJ; Lee JE; Kim MP; Aloia TA; Vauthey JN; Katz MH; Tzeng CD
HPB (Oxford); 2019 Sep; 21(9):1203-1210. PubMed ID: 30799277
[TBL] [Abstract][Full Text] [Related]
35. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
36. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
[TBL] [Abstract][Full Text] [Related]
37. Improved overall survival is still observed in patients receiving delayed adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Turner MC; Masoud SJ; Cerullo M; Adam MA; Shah KN; Blazer DG; Abbruzzese JL; Zani S
HPB (Oxford); 2020 Nov; 22(11):1542-1548. PubMed ID: 32299656
[TBL] [Abstract][Full Text] [Related]
38. Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I-II or unresected stage III pancreatic cancer.
Ma SJ; Iovoli AJ; Hermann GM; Prezzano KM; Singh AK
Cancer Med; 2019 Aug; 8(9):4110-4123. PubMed ID: 31183965
[TBL] [Abstract][Full Text] [Related]
39. Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer.
Torgeson A; Lloyd S; Boothe D; Tao R; Whisenant J; Garrido-Laguna I; Cannon GM
Cancer; 2017 Oct; 123(19):3816-3824. PubMed ID: 28621885
[TBL] [Abstract][Full Text] [Related]
40. The impact of chemotherapy sequencing on resectable pancreatic cancer by stage.
Vega EA; Kutlu OC; Salehi O; Alarcon SV; Abudalou M; Kozyreva O; Krishnan S; Lee D; Freeman R; Conrad C
Surg Oncol; 2022 Mar; 40():101694. PubMed ID: 34973593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
